Is EXACT Sciences Corporation (EXAS) a Stock to Watch After Gaining 5.18% This Week?

Monday, November 29, 2021 01:15 PM | InvestorsObserver Analysts

Mentioned in this article

EXACT Sciences Corporation (EXAS) stock is up 5.18% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

EXACT Sciences Corporation has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on EXAS!
See Full EXAS Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With EXAS Stock Today?

EXACT Sciences Corporation (EXAS) stock is trading at $88.40 as of 1:02 PM on Monday, Nov 29, a rise of $2.94, or 3.44% from the previous closing price of $85.46. The stock has traded between $85.80 and $88.60 so far today. Volume today is less active than usual. So far 901,779 shares have traded compared to average volume of 1,573,584 shares.

More About EXACT Sciences Corporation

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening. Click Here to get the full Stock Report for EXACT Sciences Corporation stock.

Share this article:

Related Articles